APA
Mahalingam D., Nemunaitis J. J., Malik L., Sarantopoulos J., Weitman S., Sankhala K., Hart J., Kousba A., Gallegos N. S., Anderson G., Charles J., Rogers J. M., Senzer N. N. & Mita A. C. (20150119). Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
Chicago
Mahalingam Devalingam, Nemunaitis John J, Malik Laeeq, Sarantopoulos John, Weitman Steven, Sankhala Kamalesh, Hart Jessica, Kousba Ahmed, Gallegos Nicole S, Anderson Gavin, Charles John, Rogers Jon M, Senzer Neil N and Mita Alain C. 20150119. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
Harvard
Mahalingam D., Nemunaitis J. J., Malik L., Sarantopoulos J., Weitman S., Sankhala K., Hart J., Kousba A., Gallegos N. S., Anderson G., Charles J., Rogers J. M., Senzer N. N. and Mita A. C. (20150119). Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology.
MLA
Mahalingam Devalingam, Nemunaitis John J, Malik Laeeq, Sarantopoulos John, Weitman Steven, Sankhala Kamalesh, Hart Jessica, Kousba Ahmed, Gallegos Nicole S, Anderson Gavin, Charles John, Rogers Jon M, Senzer Neil N and Mita Alain C. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. : Cancer chemotherapy and pharmacology. 20150119.